Episode Details

In this episode of the BioHub Podcast, Amber is joined by Daniel, Co-Founder and CEO of Model Medicines.

Model Medicines is building an AI-driven drug discovery platform with a fundamentally different approach, focusing on applying machine learning to problems where traditional methods have failed.

Daniel shares how the team is targeting biological “choke points” across multiple diseases, why throughput and inference may matter more than model size, and how they’re thinking about scaling into development as programmes move towards the clinic.